ASND Ascendis Pharma A/S
- 135.350
- +0.140+0.10%
Ascendis Pharma A/S News
Subdued Growth No Barrier To Ascendis Pharma A/S' (NASDAQ:ASND) Price
Ascendis Pharma A/S' (NASDAQ:ASND) price-to-sales (or "P/S") ratio of 22.1x might make it look like a strong sell right now compared to the Biotechs industry in the United States, where around half
$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 43.24% on an annualized basis producing an average annual return of 54.04%. Currently, Ascendis Pharma has a
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday
European equities traded in the US as American depositary receipts were moving moderately lower late Thursday morning, declining 0.72% to 1,423.26 on the S&P Europe Select ADR Index.From continental
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $260
Wells Fargo analyst Derek Archila maintains $Ascendis Pharma A/S(ASND.US)$ with a buy rating, and adjusts the target price from $262 to $260.According to TipRanks data, the analyst has a success
The Small-Cap Stock Boom Is Overdue. This Fund Is Ready.
"I can't tell you we are at the absolute bottom," says Harbor Small Cap Growth fund manager William Muggia. "But it sure smells like it."
Ascendis Pharma, Pendopharm Sign Distribution Agreement for TransCon Parathyroid Hormone in Canada
Ascendis Pharma (ASND) and Pendopharm have signed a distribution agreement under which the latter will oversee regulatory approval and commercialization of Ascendis' hypoparathyroidism treatment Trans
Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading higher on Friday morning, some of the stocks that may grab investor focus today are as follows:Arkhouse Management and Brigade Capital Management increased their offer
Express News | Reported Thursday, Pendopharm Partners With Ascendis Pharma For Exclusive Distribution of TransCon PTH In Canada
Pendopharm Signs Exclusive Distribution Agreement With Ascendis Pharma A/S for TransCon PTH in Canada
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending higher late Wednesday morning, rising 0.6% to 1,436.74 on the S&P Europe Select ADR Index. From continental Europe, the
Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 15.29% on an annualized basis producing an average annual return of 28.27%. Currently, Ascendis Pharma has a market
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were trending lower late Tuesday morning, declining 0.55% to 1,422.73 on the S&P Europe Select ADR Index. From continental Europe, th
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading
European equities traded in the US as American depositary receipts were higher Monday, rising 0.55% to 1,427.31 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by bio
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
European equities traded in the US as American depositary receipts were trending lower late Wednesday morning, falling 0.85% to 1,421.90 on the S&P Europe Select ADR Index. From continental Europe, th
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 15.22% on an annualized basis producing an average annual return of 27.98%. Currently, Ascendis Pharma has a market
Top Gap Ups and Downs on Tuesday: NVO, TM, MUFG and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading
European equities traded in the US as American depositary receipts were trending slightly higher late Tuesday morning, rising 0.18% to 1,428.31 on the S&P Europe Select ADR Index. From continental Eur
TD Cowen Upgrades Ascendis Pharma A/S(ASND.US) to Buy Rating, Raises Target Price to $175
TD Cowen analyst Yaron Werber upgrades $Ascendis Pharma A/S(ASND.US)$ to a buy rating, and adjusts the target price from $156 to $175.According to TipRanks data, the analyst has a success rate of 57.7
Ascendis Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/25/2024 35.25% TD Cowen $156 → $175 Upgrades Hold → Buy 05/31/2024 54.57% Stifel → $200 Initiates Cover
Express News | Ascendis Pharma A/S : TD Cowen Raises Target Price to $175 From $156
Analysis
Price Target
No Data
